This page shows the latest IBD news and features for those working in and with pharma, biotech and healthcare.
Sponsored by Cloud Talk. Winner: LOGIC IBD Nurse Education and Recognition Event.
Tremfya also has data suggesting it works in Stelara-resistant psoriasis. Lilly’s antibody is still in phase 3 for psoriasis, well behind the leaders, but IBD presents a greater opportunity
Finch's CEO Mark Smith. Led by CEO Mark Smith, the company also has a two-year-old deal with Takeda to develop a microbiota treatment for irritable bowel disease (IBD).
The two companies have started treating patients in a phase 1 trial of VE202, another bacterial consortium aimed at treating inflammatory bowel disease (IBD). ... VE202 is based on the idea that IBD patients are deficient in certain Clostridia species in
Specialist healthcare communications group Sciterion (pictured below) won the Excellence in Communications via a Live Event or Stand-Alone Activity accolade for its Live Multi-site National IBD Meeting. ... Meanwhile, Aurora Healthcare Communications’
More from news
Approximately 11 fully matching, plus 32 partially matching documents found.
It has been a game changer for IBD patients and the EMA decision means that they have greater choice. ... Projects that address gut inflammation beyond IBD are focused on coeliac disease, acute pancreatitis and short bowel syndrome.
The solution was a dual-aspect meeting: The ‘LOGIC IBD Nurse Education Day and Recognition Event’. ... IBD nurses had limited support with personal development and raising their profile within their hospital/Trust.
It was originally planned to run alongside a successful national IBD Audit programme managed by the Royal College of Physicians (RCP). ... In 2015 NHS England announced it was pulling the Audit funding and recommended that future audits be incorporated
The deal also includes a licence to AKB-5169 (formerly JNJ5169), an oral, preclinical stage compound for inflammatory bowel disease (IBD). . ... Joint venture. 286.3. Janssen/ Akebia Therapeutics. HIF-targeting candidates inc AKB-5169 for IBD (pc)
IBD). PF-00547659 targets a gastrointestinal endothelial adhesion molecule known as mucosal addressin cell adhesion molecule 1 (MAdCAM-1) that binds to the α4β7 integrin on lymphocytes.
More from intelligence
Approximately 1 fully matching, plus 11 partially matching documents found.
Takeda UK has appointed Craig Adkins as its new business unit director for irritable bowel disease (IBD). .
More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.
Asians. Health outcomes for IBD are poorer among African Americans vs white Americans. ... In some cultures, an IBD diagnosis is associated with stigma, which can impact the patient journey.
She has experience across several different therapy areas, including diabetes, rare diseases and IBD.
Lizzie has previously worked in Global, European, and UK roles with experience in several therapy areas including immuno-oncology, CIA, CKD, oral contraception, IBD, and wound care.
The IBD Registry is familiar to many as the first UK-wide collection of anonymised adult and paediatric IBD data for prospective audit and research. ... Liz brings to the IBD Registry 20 years of executive and senior management experience from the
Recently, we spoke to members of the IBD Registry Industry Working Group about what they’ve achieved in their first year, and whether or not it’s been worthwhile.
More from PMHub
Approximately 3 fully matching, plus 19 partially matching documents found.
MadMicrobe is an award-winning team of certified medical illustrators creating animations that draw audiences into a world of suspense, excitement,...